Physician profile

Jack C Rosenfeld

Family Medicine · Lansdale, PA

NPI 1558368811

$6,778.02

in general payments reported to CMS, 2019-2025

53 companies · none reported in 2025

See the full distribution for Family Medicine

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,540.03

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $1,037.00 2019-2023 Ubrelvy, Vraylar, Viberzi
Glaxosmithkline, LLC. $757.08 2019-2023 Shingrix, Bexsero, Trelegy Ellipta
Novo Nordisk INC $502.43 2019-2023 Wegovy
Astrazeneca Pharmaceuticals LP $469.11 2019-2023 Farxiga, Breztri
Lilly USA, LLC $431.34 2019-2023 Jardiance, Mounjaro, Trulicity
Kowa Pharmaceuticals America, INC. $387.31 2019-2022
Merck Sharp & Dohme LLC $387.08 2019-2023 Belsomra, Verquvo, Steglatro
Sanofi-Aventis U.S. LLC $320.87 2019-2023
Amarin Pharma, INC. $289.52 2019-2023
Pfizer INC. $259.95 2019-2023
Bayer Healthcare Pharmaceuticals INC. $182.31 2021-2023
Amgen INC. $152.10 2019-2023 Otezla, Repatha
Allergan, INC. $149.28 2019-2020
Daiichi Sankyo INC. $148.27 2020-2022
Abbott Laboratories $139.34 2021-2023 Freestyle Libre 2
Show all 50 companies
CompanyGeneral paymentsYearsTop products
Dexcom, INC. $99.29 2021-2023 Dexcom G6 Transmitter
Boehringer Ingelheim Pharmaceuticals, INC. $80.42 2019-2022
Janssen Pharmaceuticals, INC $69.77 2019-2022
Bausch Health US, LLC $60.07 2022-2023 Wellbutrin, Aplenzin
Exact Sciences Corporation $57.41 2023 Cologuard Collection Kit
Corium, LLC $57.21 2023 Adlarity
Biohaven Pharmaceuticals, INC. $55.94 2020-2021
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $54.80 2019-2023 Xifaxan, Trulance
Takeda Pharmaceuticals U.S.A., INC. $53.39 2019
Biohaven Pharmaceutical Holding Company LTD. $48.10 2022
Novartis Pharmaceuticals Corporation $47.15 2019-2021
Harmony Biosciences LLC $43.23 2022
Alkermes, INC. $36.07 2022-2023 Vivitrol
Nalpropion Pharmaceuticals LLC $33.34 2019
Sanofi Pasteur INC. $31.79 2019-2021
Celgene Corporation $28.14 2019
Ibsa Pharma INC. $21.45 2019
Ironshore Pharmaceuticals INC. $20.98 2023 Jornay Pm
Vbi Vaccine (Delaware) INC. $20.95 2022
Genentech USA, INC. $20.60 2020
Optinose US, INC. $18.53 2021
Edwards Lifesciences Corporation $18.52 2022
Avanir Pharmaceuticals, INC. $18.50 2019
Impel Pharmaceuticals INC. $17.96 2023 Trudhesa
Linus Health, INC. $16.65 2023
Eisai INC. $15.60 2021
Kaleo, INC. $15.52 2022
Vertos Medical, INC. $14.49 2019
Teva Pharmaceuticals USA, INC. $14.29 2021
Seqirus USA INC $14.25 2021
Idorsia Pharmaceuticals US INC $13.65 2023 Quviviq
Topcon Healthcare Solutions, INC. $13.55 2022
Circassia INC. $11.77 2020
Vistapharm, INC. $11.05 2021
Ultragenyx Pharmaceutical INC. $10.60 2019

3 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$1,190.13 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jack C Rosenfeld

$6,778.02

in general payments reported 2019-2025

Years
2019-2023
Top company
Eli Lilly and Company

https://glasscript.com/doctor/115603/jack-c-rosenfeld

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.